Featured Research

from universities, journals, and other organizations

Immune system linked with accumulation of toxic tau protein

Date:
October 7, 2010
Source:
Cell Press
Summary:
Cells that help to protect the central nervous system may also contribute to pathological changes in the brain. New research provides mechanistic insight into a link between the immune system and neurodegenerative disorders like Alzheimer's disease that are associated with abnormal accumulation of tau protein.

Cells that help to protect the central nervous system may also contribute to pathological changes in the brain. New research, published by Cell Press in the October 7th issue of the journal Neuron, provides mechanistic insight into a link between the immune system and neurodegenerative disorders like Alzheimer's disease that are associated with abnormal accumulation of tau protein.

Tau is a protein found inside of neurons that acts almost like a skeleton, providing a supportive framework for the cell. However, abnormal tau sometimes clumps into filamentous deposits that damage neurons. It is well established that aggregates of microtubule associated protein tau (MAPT) with multiple phosphate groups attached are a defining feature of neurodegenerative disorders called "tauopathies," which include some movement disorders along with Alzheimer's disease and other dementias. Tauopathies are increasingly common neurodegenerative diseases with over 5 million people in the US with AD and millions more affected by non-AD tauopathies.

Previous research suggested a link between inflammation in the nervous system and the tauopathies. More specifically, cells called microglia which play a key role in the immunity of the nervous system have been implicated in the pathogenesis of multiple neurodegenerative disorders. "While some research has suggested a correlative link between neuroinflammation and tauopathies, there is little mechanistic evidence that altered microglial activation plays a pathogenic role in the formation of MAPT pathologies," explains senior study author, Dr. Bruce T. Lamb from the Department of Neurosciences at the Cleveland Clinic.

In order to examine the link between microglia and tauopathy, Dr. Lamb and colleagues studied a specific signaling pathway through which neurons and microglia communicate, fractalkine (CX3CL1), a chemokine expressed in neurons, and its receptor (CX3CR1) which is expressed exclusively in microglia. Dr. Lamb's group evaluated perturbations of this signaling pathway in several different model systems, including a mouse model of inflammation, a mouse model of tauopathy (hTau) and microglia and neurons grown in the laboratory. They found that microglial inflammation promoted MAPT phosphorylation and aggregation in all of the model systems.

"Importantly, introduction of CX3CR1 deficiency into hTau mice resulted in altered microglial activation, enhanced MAPT phosphorylation and aggregation, as well as behavioral abnormalities," says Dr. Lamb. In addition to documenting the effects of a specific microglial receptor on MAPT pathology, the researchers also gained new insight into specific signaling molecules downstream of the CX3CL1/CX3CR1 interaction. Taken together, the findings reveal a direct link between the activation of microglia and the abnormal phosphorylation and aggregation of MAPT in neurons and suggest potential novel therapeutic strategies for tauopathies.

The researchers include Kiran Bhaskar, Cleveland Clinic Foundation, Cleveland, OH; Megan Konerth, Cleveland Clinic Foundation, Cleveland, OH; Olga N. Kokiko-Cochran, Cleveland Clinic Foundation, Cleveland, OH; Astrid Cardona, Cleveland Clinic Foundation, Cleveland, OH, Case Western Reserve University School of Medicine, Cleveland, OH; Richard M. Ransohoff, Cleveland Clinic Foundation, Cleveland, OH; and Bruce T. Lamb, Cleveland Clinic Foundation, Cleveland, OH, Case Western Reserve University School of Medicine, Cleveland, OH.


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Journal Reference:

  1. Kiran Bhaskar, Megan Konerth, Olga N. Kokiko-Cochran, Astrid Cardona, Richard M. Ransohoff, Bruce T. Lamb. Regulation of Tau Pathology by the Microglial Fractalkine Receptor. Neuron, 2010; 68 (1): 19-31 DOI: 10.1016/j.neuron.2010.08.023

Cite This Page:

Cell Press. "Immune system linked with accumulation of toxic tau protein." ScienceDaily. ScienceDaily, 7 October 2010. <www.sciencedaily.com/releases/2010/10/101006131201.htm>.
Cell Press. (2010, October 7). Immune system linked with accumulation of toxic tau protein. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2010/10/101006131201.htm
Cell Press. "Immune system linked with accumulation of toxic tau protein." ScienceDaily. www.sciencedaily.com/releases/2010/10/101006131201.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins